Ginsenoside-Re-Ginsenoside-B2-DataSheet-MedChemExpress_第1页
Ginsenoside-Re-Ginsenoside-B2-DataSheet-MedChemExpress_第2页
Ginsenoside-Re-Ginsenoside-B2-DataSheet-MedChemExpress_第3页
Ginsenoside-Re-Ginsenoside-B2-DataSheet-MedChemExpress_第4页
全文预览已结束

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEGinsenoside ReCat. No.: HY-N0044CAS No.: 52286-59-6Synonyms: Ginsenoside B2; Panaxoside Re; Sanchinoside Re分式: CHO分量: 947.15作靶点: Amyloid-; NF-B; JNK作通路: Neuronal Signaling; NF-B; MAPK/ERK Pathway储存式: Powder -20C 3 years4C 2 year

2、sIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 50 mg/mL (52.79 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 1.0558 mL 5.2790 mL 10.5580 mL5 mM 0.2112 mL 1.0558 mL 2.1116 mL10 mM 0.1056 mL 0.5279 mL 1.0558 mL请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液,并请注意储备液的

3、保存式和期限。体内实验请根据您的实验动物和给药式选择适当的溶解案,配制前请先配制澄清的储备液,再依次添加助溶剂(为保证实验结果的可靠性,体内实验的作液,建议您现现配,当天使;澄清的储备液可以根据储存条件,适当保存;以下溶剂前的百分 指该溶剂在您配制终溶液中的体积占):1. 请依序添加每种溶剂: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (2.64 mM); Clear solution2. 请依序添加每种溶剂: 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.

4、5 mg/mL (2.64 mM); Clear solution1/3 Master of Small Molecules 您边的抑制剂师www.MedChemE3. 请依序添加每种溶剂: 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (2.64 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Ginsenoside Re (Ginsenoside B2)种 Panax notoginseng 提取物。Ginsenoside Re 可降低 -淀粉样蛋(A)。Ginsenoside Re 还通过抑制 JNK 和 NF-

5、B 发挥抗炎作。IC50 & Target NF-B JNK A1-40 A1-42体外研究 Ginsenoside Re is a well-known traditional Chinese medicine, which decreases the -site amyloid precursorprotein cleaving enzyme 1 (BACE1) mRNA and protein levels and inhibits BACE1 activity in the N2a/APP695cells. Ginsenoside Re also significantly incre

6、ases the PPAR protein and mRNA levels.To preventGinsenoside Re from having a cytotoxic effect on the N2a/APP695 cells, the cell viability is first determinedby the MTT assay. The N2a/WT and N2a/APP695 cells are treated with increasing concentrations ofGinsenoside Re (0-200 M) for 24 h. Ginsenoside R

7、e concentrations under 100 M do not affect the viabilityof the N2a/WT and N2a/APP695 cells, whereas the 150 M Ginsenoside Re concentration markedlydecreases the survival rate of the N2a/WT and N2a/APP695 cells. Incubation with Ginsenoside Re at a 200M concentration for 24 h reduces the viability of

8、the N2a/WT and N2a/APP695 cells by 15.58% and 26.82%,respectively. These data indicate that Ginsenoside Re treatment within the range of 0-100 M for 24 h is safefor the N2a/WT and N2a/APP695 cells (P0.05) 1.体内研究 Ginsenoside Re reduces insulin resistance in 3T3-L1 adipocytes and high-fat diet (HFD) r

9、ats throughinhibition of JNK and NF-B activation 2. Intraperitoneal injection of lipopolysaccharide (LPS) at a dose of20 mg/kg is lethal to mice, and 70% to 80% of the mice die within 60 h. However, pretreatment of the micewith Rg1 or Ginsenoside Re increases their survival rates in a dose-dependent

10、 manner. With the doses ofRg1 or Ginsenoside Re increase from 2.5 to 5 mg/kg, the survival rate is elevated from 60% to 90% (Rg1) orfrom 30% to 40% (Ginsenoside Re). All the mice administered Rg1 at a minimal dose of 10 mg/kg areprotected from death compared to 80% survival of mice treated with an e

11、qual dose of Ginsenoside Re. Toprotect all the mice, 20 mg/kg Ginsenoside Re is needed. To investigate the anti-inflammatory potential ofRg1 and Ginsenoside Re, 1 mg/kg Rg1 or Ginsenoside Re is injected into rats and then challenged theanimals with LPS. The injection procedure itself causes a transi

12、ent stress-induced increase in bodytemperature of 1.2C in each group. Thereafter, LPS-challenged rats without pretreatment develope arobust biphasic fever, with the first peak reaching 1.5C at 2 h and the second peak reaching 1.8C at 4 h.In contrast, the temperature changes for the Rg1-, Ginsenoside

13、 Re-, and TAK-242-treated groups are only0.9, 1.2, and 0.8C at 2 h and 1.3, 1.4, and 1.0C at 4 h, respectively. Pretreatment with Rg1, GinsenosideRe, or TAK-242 significantly attenuates LPS-induced alterations in body temperature 3.PROTOCOLCell Assay 1 To explore the cytotoxic effect of Ginsenoside

14、Re on N2a/APP695 cells, cell proliferation is assessed usingthe MTT assay. The cells are treated with increasing doses of Ginsenoside Re (0, 25, 50, 100, 150, and 2002/3 Master of Small Molecules 您边的抑制剂师www.MedChemEM) for 24 h. The MTT assay is performed after the treatments. The cells are incubated

15、 for 4 h at 37 C with0.5 mg/mL of MTT dissolved in fresh complete medium. The dark blue formazan crystals are dissolved inDMSO, and the absorbance is measured on a microplate reader using a reference wavelength of 630 nmand a test wavelength of 490 nm. The data are expressed as the mean percentages

16、of viable cells versus thecontrol 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice 3Administration 3 To examine the prophylactic effect of Rg1 and Ginsenoside Re on LPS-induced lethality, 6- to 8-week-oldBALB/c mice are randomly assigned to

17、 7 groups with 10 mice in each group. The mice are either leftuntreated or subcutaneously injected with 2.5, 5, 10, or 20 mg/kg Rg1, 20 mg/kg Ginsenoside Re, or 5 mg/kgTAK-242 3 times at 30-min intervals and then challenged with LPS (20 mg/kg) 15 min later. To test thetherapeutic effect of Rg1 and G

18、insenoside Re on LPS-induced lethality, BALB/c mice are assigned to 5groups with 10 mice in each group. The mice are injected intraperitoneally (i.p.) with 20 mg/kg LPS. Fifteenminutes later, mice are subcutaneously injected with 10 mg/kg Rg1, 20 mg/kg Ginsenoside Re, or 5 mg/kgTAK-242 3 times at 30

19、-min intervals or left untreated. Survival rates are recorded for 60 h.Rats 3Sprague Dawley rats are intravenously administered saline solution, 1 mg of Rg1/kg body weight (1 mg/kgRg1), 1 mg/kg Ginsenoside Re, or 1 mg/kg TAK-242. Fifteen minutes later, rats are challenged with 2.5 g/kgLPS. Body temp

20、erature is measured before and after drug administration. Anticoagulated blood samples withEDTA are collected for white blood cell (WBC) counts at indicated time points using a ProCyte Dx automaticblood cell analyzer. Additional blood samples are collected at 4 h post-drug injection and used for pre

21、parationof serum to analyze proinflammatory mediators. The proinflammatory cytokine responses are detected byWestern blot assay.MCE has not independently confirmed the accuracy of these methods. They are for reference only.户使本产品发表的科研献 J Neurosci Res. 2019 Aug 16.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Cao G, et al. Ginsenosi

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论